Condition: Relapsed/Refractory KMT2A-r Acute Leukemia · Relapsed/Refractory NUP98-r Acute Leukemia · Relapsed/Refractory NPM1-m Acute Leukemia · Sponsor: PedAL BCU, LLC
The primary objective of the study is to determine the recommended phase 2 dose (RP2D) of ziftomenib in combination with chemotherapy (FLA) in children with relapsed or refractory KMT2A-r, NUP98-r, or NPM1-m acute leukemia based on safety and pharmacokinetics (PK).
This description comes directly from the study's public registry record.
Dr. Branko Cuglievan · (713) 563-1499 · bcuglievan@mdanderson.org
Dr. Sarah Tasian, MD · (215) 590-2299 · tasians@chop.edu
Always discuss trial participation with your own doctor first.
| Children's Hospital Los Angeles | Los Angeles, California, United States | Recruiting |
| Children's Hospital Colorado | Aurora, Colorado, United States | Recruiting |
| Children's Healthcare of Atlanta | Atlanta, Georgia, United States | Recruiting |
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago, Illinois, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center - New York | New York, New York, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| St. Jude Children's Research Hospital | Memphis, Tennessee, United States | Recruiting |
| Texas Children's Hospital | Houston, Texas, United States | Recruiting |
| Seattle Children's Hospital | Seattle, Washington, United States | Recruiting |
| Sankt Anna-Kinderspital | Vienna, State of Vienna, Austria | Recruiting |
+ 8 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06376162